ClinicalTrials.gg
Active, not recruitingNCT05542706AIDORLUpdated Nov 4, 2026

Benefit of Paramedical Care in Accompanying Caregivers of Patients That Had Surgery for an Head and Neck Invasive Cancer

An interventional study of Accompanying caregivers by paramedical team in Head and Neck Cancer, sponsored by Centre Henri Becquerel. Active, not recruiting at 1 site in France. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Centre Henri Becquerel · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 4, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 236 studies in Head and Neck Neoplasms with a site in France — 49 open to participants now, 69 under way, 11 of them phase 3. Head and Neck Neoplasms · France.

Enrollment
142nd of 197
48 · median 110
Started
2022
with 12 others
No phase
63 of 236
22 open now
Primary completion
2026-10
later than 19 of 68 live
Registered
191st of 236
by date
Lead sponsor
6 of 236
Centre Henri Becquerel

Among the 236 studies in Head and Neck Neoplasms with a site in France, this one is the 142nd largest by enrollment of the 197 interventional ones that give a count, is one of 13 that started in 2022, is one of 63 with no phase, reaches primary completion later than 19 of the 68 other live ones, and was the 191st registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

49 of the 236 studies in Head and Neck Neoplasms with a site in France are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Head and Neck Neoplasms with a site in France, or all of them as a file.
02

Study summary

Head and Neck invasive cancer usually requires surgery that is associated with modifications of the body structure of patient regarding breathing, eating and communication. These modifications are correlated with an important loss of autonomy in patients. During the study, while the patient is hospitalised after the surgery, the paramedical team will train the caregiver of the patient from experimental group a new dimension of autonomy in order to assure a safe return home. The level of learning depends on each caregiver and patient; therefore, an adapted training is provided.

This study evaluates the impact of paramedical care in accompanying caregivers of patients that had surgery for an ENT invasive cancer, by comparing the experimental group (paramedical care) to the standard group (standard care).

The hypothesis of the study is that a benefit will be seen in the experimental group, by reducing the caregiver burden, improving the quality of life of patients and lowering the rate of hospitalisations and prolonged hospitalisations in these patients.

03

Conditions studied

  • Head and Neck Cancer
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 85 years old
  • ≤ 2
  • Patient diagnosed with an head and neck squamous-cell carcinoma, stage T2-T4/N+, non-, localised at larynx, pharynx, oropharynx, oral cavity or maxillary, needing curative surgery, with indication of radiotherapy after surgery, in accordance to decision of the regular multidisciplinary meetings in cancerology
  • No ongoing measure of corrective justice for the patient
  • form signed
  • Patient covered by health system

Exclusion criteria

Exclusion Criteria:

  • Patient scheduled for surgery after radiotherapy or for surgery on site already irradiated
  • Patient or caregiver that do not agree to participate in the study (the pair patient-caregiver is needed)
  • History of psychological or sensorial disorder or anomaly that can prevent the patient from understanding the conditions for study participation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Accompanying caregivers by paramedical team

    Other: Accompanying caregivers by paramedical team

  • No intervention
    No dedicated accompanying by medical team

Interventions

  • OtherAccompanying caregivers by paramedical team

    At each study visit (baseline, one week after hospital discharge, 4-8 weeks after surgery, 8-12 weeks after surgery and 16-20 weeks after surgery), the paramedical team have a dedicated meeting with the caregiver of the patient (at hospital or remote) and teach them the care procedures needed in accompanying the patient and the evaluate the learning progress. The training is adapted to each caregiver, according to his/her motivation and his/her ability. The goal is to have the training regarding the enteral nutrition, prevention of dehydration, pain management.

06

What researchers measure

Primary outcomes

  1. Comparison of the impact of paramedical care on the caregiving burden between the two groups

    Via Zarit Burden Interview

    Time frame: At 20 weeks after surgery

Secondary outcomes

  1. Comparison of the impact of paramedical care on the caregiving burden between the two groups

    Via Zarit Burden Interview

    Time frame: At 8 weeks after surgery

  2. Comparison of the impact of paramedical care on the caregiving burden between the two groups

    Via Zarit Burden Interview

    Time frame: At 12 weeks after surgery

  3. Measure of quality of life in the two groups

    WHOQOL-26

    Time frame: baseline

  4. Measure of quality of life in the two groups

    QLQ-H\&N35

    Time frame: baseline

  5. Measure of quality of life in the two groups

    QLQ-H\&N35

    Time frame: one week after hospital discharge

  6. Measure of quality of life in the two groups

    WHOQOL-26

    Time frame: one week after hospital discharge

  7. Measure of quality of life in the two groups

    QLQ-H\&N35

    Time frame: between 4 and 8 weeks after surgery

  8. Measure of quality of life in the two groups

    WHOQOL-26

    Time frame: between 8 and 12 weeks after surgery

  9. Measure of quality of life in the two groups

    WHOQOL-26

    Time frame: between 16 and 20 weeks after surgery

  10. Measure of quality of life in the two groups

    Via QLQ-H\&N35

    Time frame: between 16 and 20 weeks after surgery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Oct 2026, 47 months.

Of 440 non-industry interventional studies with no phase under Head and Neck Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's 47 months is above that.

Counting every sponsor, half of 458 studies reached it within 33 months; a quarter within 18 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2022
First posted
Sep 15, 2022
StartActual
Oct 31, 2022
Primary completionActual
Oct 30, 2026
CompletionEst.
Oct 31, 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 4, 2026
Primary completion
Oct 31, 2026→Oct 30, 2026 (actual)
Nov 4, 2026
Enrollment
76 (estimated)→48 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Recruiting→Active, not recruiting
    Primary completion Oct 31, 2026→Oct 30, 2026 (now actual)
    Enrollment 76 (estimated)→48 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05542706
Lead sponsor
Centre Henri Becquerel
Responsible party
Sponsor
First posted
Sep 15, 2022
Start date
Oct 31, 2022
Primary completion
Oct 30, 2026
Completion
Oct 31, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Yveline David
principal investigator · Centre Henri Becquerel

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion